OSE Immunotherapeutics — Spotlight on OSE’s diverse clinical pipeline
OSE Immunotherapeutics has made tangible progress across its clinical development pipeline, creating positive momentum, in our view. In...
357 Views
OSE Immunotherapeutics — New UC biomarker underpins growth strategy
OSE has announced plans to strengthen its growth strategy and accelerate the key pillars of its pipeline, covering immuno-inflammation and...
319 Views
OSE Immunotherapeutics — ASCO 2025 update showcases Tedopi potential
OSE Immunotherapeutics presented multiple updates at the 61st Annual American Society of Clinical Oncology Conference (ASCO 2025) related to...
341 Views
OSE Immunotherapeutics — ASCO 2025 update showcases Tedopi potential
OSE Immunotherapeutics presented multiple updates at the 61st Annual American Society of Clinical Oncology Conference (ASCO 2025) related to...
300 Views
OSE Immunotherapeutics — Strategic collaboration in mRNA technologies
OSE Immunotherapeutics has announced a new strategic collaboration with Inside Therapeutics and MiNT Laboratory (University of Angers) to develop...
338 Views